Protagonist Therapeutics Valuation
| PTGX Stock | USD 37.80 0.16 0.42% |
At this time, the company appears to be undervalued. Protagonist Therapeutics holds a recent Real Value of $48.7 per share. The prevailing price of the company is $37.8. Our model determines the value of Protagonist Therapeutics from analyzing the company fundamentals such as Shares Outstanding of 59.6 M, operating margin of (8.87) %, and Return On Equity of 0.41 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Protagonist Therapeutics' valuation include:
Price Book 4.3832 | Enterprise Value | Enterprise Value Ebitda 12.3021 | Price Sales 7.2005 | Forward PE 26.3852 |
Undervalued
Today
Please note that Protagonist Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Protagonist Therapeutics is based on 3 months time horizon. Increasing Protagonist Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Protagonist Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Protagonist Stock. However, Protagonist Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 37.8 | Real 48.7 | Target 57.5 | Hype 37.49 | Naive 39.0 |
The intrinsic value of Protagonist Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Protagonist Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Protagonist Therapeutics helps investors to forecast how Protagonist stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Protagonist Therapeutics more accurately as focusing exclusively on Protagonist Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Protagonist Therapeutics' intrinsic value based on its ongoing forecasts of Protagonist Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Protagonist Therapeutics' closest peers.
Protagonist Therapeutics Cash |
|
Protagonist Valuation Trend
Analysing the historical paterns of Protagonist Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Protagonist Therapeutics over time and is usually enough for investors to make rational market timing decisions.
Protagonist Therapeutics Total Value Analysis
Protagonist Therapeutics is at this time forecasted to have valuation of 1.87 B with market capitalization of 2.33 B, debt of 1.14 M, and cash on hands of 291.89 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Protagonist Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.87 B | 2.33 B | 1.14 M | 291.89 M |
Protagonist Therapeutics Investor Information
About 99.0% of the company shares are owned by institutional investors. The book value of Protagonist Therapeutics was at this time reported as 8.94. The company had not issued any dividends in recent years. Based on the key indicators related to Protagonist Therapeutics' liquidity, profitability, solvency, and operating efficiency, Protagonist Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Protagonist Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Protagonist Therapeutics has an asset utilization ratio of 16.76 percent. This suggests that the Company is making $0.17 for each dollar of assets. An increasing asset utilization means that Protagonist Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Protagonist Therapeutics Ownership Allocation
The majority of Protagonist Therapeutics outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Protagonist Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Protagonist Therapeutics. Please pay attention to any change in the institutional holdings of Protagonist Therapeutics as this could imply that something significant has changed or is about to change at the company.Protagonist Therapeutics Profitability Analysis
The company reported the previous year's revenue of 60 M. Net Loss for the year was (78.95 M) with profit before overhead, payroll, taxes, and interest of 323.8 M.About Protagonist Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Protagonist Therapeutics. We calculate exposure to Protagonist Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Protagonist Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 69 M | 72.5 M | |
| Pretax Profit Margin | (1.18) | (1.24) | |
| Operating Profit Margin | (1.40) | (1.48) | |
| Net Loss | (1.18) | (1.24) | |
| Gross Profit Margin | 0.87 | 0.74 |
Protagonist Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 56.8 M | |
| Forward Price Earnings | 26.3852 |
Protagonist Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Protagonist Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Protagonist we look at many different elements of the entity such as Protagonist's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Protagonist Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Protagonist Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Protagonist Therapeutics' worth.Additional Tools for Protagonist Stock Analysis
When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.